17,159 Abbott Laboratories $ABT Shares Sold by Simplify Asset Management Inc.

Simplify Asset Management Inc. cut its holdings in Abbott Laboratories (NYSE:ABT - Free Report) by 83.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,387 shares of the healthcare product maker's stock after selling 17,159 shares during the quarter. Simplify Asset Management Inc.'s holdings in Abbott Laboratories were worth $335,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. BlackRock Inc. grew its holdings in Abbott Laboratories by 4.6% during the 2nd quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker's stock valued at $13,843,610,000 after buying an additional 6,769,518 shares during the last quarter. State Street Corp increased its position in Abbott Laboratories by 1.7% during the second quarter. State Street Corp now owns 80,926,234 shares of the healthcare product maker's stock worth $7,343,246,000 after buying an additional 1,350,766 shares in the last quarter. Bank of America Corp DE acquired a new position in Abbott Laboratories in the 2nd quarter valued at about $1,603,607,000. Deutsche Bank AG lifted its holdings in Abbott Laboratories by 18.6% in the 2nd quarter. Deutsche Bank AG now owns 16,706,669 shares of the healthcare product maker's stock valued at $1,515,963,000 after purchasing an additional 2,614,965 shares in the last quarter. Finally, Legal & General Group Plc purchased a new position in Abbott Laboratories in the 2nd quarter valued at about $1,082,524,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott launched a next-generation Oncodetect test designed to detect residual cancer disease, expanding its diagnostics portfolio and potentially supporting longer-term growth in oncology testing. Abbott Launches Next-Generation Oncodetect Test
• Positive Sentiment: The planned spin-off of Abbott’s Nutrition segment, which generates approximately $8.5 billion in annual sales, could allow the remaining company and the new standalone business to pursue more focused strategies. Abbott has appointed Daniel Salvadori to lead the future Nutrition company. What Could Abbott Laboratories Spin Off Mean for Its Future Growth?
• Positive Sentiment: Abbott received approximately $23.9 million in net ETF buying, indicating some continued institutional demand for ABT shares despite recent volatility. Abbott Sees $23.9 Million in Net ETF Buying
• Neutral Sentiment: Abbott is included in coverage of Europe’s medical foods market, which is projected to grow from $6.5 billion in 2026 to $7.9 billion by 2033. The outlook highlights a long-term opportunity for Abbott’s specialized nutrition business, though it does not represent new company-specific revenue. Europe Medical Foods Market Strategic Outlook
• Negative Sentiment: Argus Research downgraded Abbott from “Buy” to “Hold,” reportedly citing a guidance cut. The change removes a bullish rating catalyst and reinforces investor concerns about near-term demand and earnings visibility. Abbott Downgraded at Argus on Guidance Cut
• Negative Sentiment: Higher interest-rate expectations are creating pressure on richly valued quality-growth stocks such as Abbott, as elevated rates can reduce the value investors assign to future earnings. Demand headwinds and litigation risks are also cited as concerns. Abbott Demand Headwinds and Litigation Risks

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Citigroup decreased their price target on shares of Abbott Laboratories from $125.00 to $122.00 and set a "buy" rating on the stock in a research note on Thursday, October 22nd. Rothschild & Co Redburn raised shares of Abbott Laboratories from a "neutral" rating to a "buy" rating and boosted their price objective for the company from $119.00 to $127.00 in a research report on Friday, October 2nd. JPMorgan Chase & Co. reduced their price objective on shares of Abbott Laboratories from $120.00 to $118.00 and set an "overweight" rating on the stock in a research note on Thursday, October 22nd. Piper Sandler reissued an "overweight" rating and set a $118.00 price objective (up from $115.00) on shares of Abbott Laboratories in a research note on Friday, July 17th. Finally, Wells Fargo & Company raised their target price on shares of Abbott Laboratories from $112.00 to $119.00 and gave the stock an "overweight" rating in a research report on Thursday, October 22nd. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $118.32.

Abbott Laboratories Stock Down 0.4%

Shares of ABT opened at $102.66 on Thursday. The firm has a market cap of $177.64 billion, a PE ratio of 38.31, a price-to-earnings-growth ratio of 1.82 and a beta of 0.59. The company's fifty day moving average is $104.72 and its two-hundred day moving average is $102.26. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $132.02. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings data on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.42. The company had revenue of $13.01 billion during the quarter, compared to analysts' expectations of $12.99 billion. Abbott Laboratories had a net margin of 9.75% and a return on equity of 17.97%. The business's quarterly revenue was up 14.5% compared to the same quarter last year. During the same period in the previous year, the company earned $1.30 EPS. Analysts forecast that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be issued a $0.63 dividend. The ex-dividend date is Thursday, October 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.5%. Abbott Laboratories's dividend payout ratio (DPR) is presently 94.03%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women's health and cardiometabolic care.

The company's nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.